This is a working overview of Tesamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Hydrostatic skeletons are flexible cavities within an animal that provide structure through fluid pressure, occurring in some types of soft-bodied organisms, including jellyfish, flatworms, nematodes, and earthworms. The walls of these cavities are made of muscle and connective tissue. In addition to providing structure for an animal's body, hydrostatic skeletons transmit the forces of muscle contraction, allowing an animal to move by alternating contractions and expansions of muscles along the animal's length.
British Pharmacopoeia (BP): Purified water Japanese Pharmacopoeia (JP): Purified water European Pharmacopoeia (Ph Eur): Aqua purificata The United States Pharmacopoeia (USP): Purified water Note: Purified Water is typically a main monograph which references other applications that use Ultrapure water Ultrapure water is often used as a critical utility for cleaning applications (as required). It is also used to generate clean steam for sterilization. The following table summarizes the specifications of two major pharmacopoeias for 'water for injection': Pharmacopoeia specifications for water for injection
The filmmakers decided that Dredd should appear lean and fast like a boxer rather than bulky like "someone who spends hours sort of steroiding himself up." His Judge uniform was altered from the comic version; an extruded eagle statuette was removed from his shoulder pad to emphasise the outfit's functionality and give it a sense of realism. Garland said: "If you did a very faithful adaptation of the uniform you'd have someone who if he got stabbed in the stomach he'd be in big trouble. Dredd is out there on the frontline so he needed protection." Remaining faithful to the comic, Dredd's face, except for his mouth, is never shown and his helmet is not removed throughout the film. Urban said: "He is supposed to be the faceless representative of the law and I think that is part of his enigma ... You wouldn't get to the end of a Sergio Leone Western and go, 'God, I didn't even know the character's name!' It's irrelevant." Dredd's signature weapon, the "Lawgiver" was developed as a fully operational weapon based on a 9mm firing system, capable of firing ammunition and being changed from automatic to semi-auto fire. His motorcycle "Lawmaster" was a modified 500cc motorcycle. A large fairing was added over the motorcycle with machine guns, an extended wheel base and the largest functional tyres possible. The vehicle was also operational and Urban insisted on riding it himself rather than relying on green-screen visual effects.
Sources: en.wikipedia.org
The pelvis was a large structure. Its upper bone, the ilium, was both very long and high, providing an extensive attachment area for hindlimb muscles. The front pubic bone ended in an enormous pubic boot, longer than the entire shaft of the element. The rear ischium was slender and straight, pointing obliquely to behind and below. In contrast to the arms, the hindlimbs were among the longest in proportion to body size of any theropod. In the foot, the metatarsus was "arctometatarsalian", meaning that the part of the third metatarsal near the ankle was pinched. The third metatarsal was also exceptionally sinuous. Compensating for the immense bulk of the animal, many bones throughout the skeleton were hollowed, reducing its weight without significant loss of strength.
=== Surgery === A surgery of any type inherently carries more risks when done on a patient who has (especially moderate to severe) OI. Skeletal deformities and dentinogenesis imperfecta may hinder access to the airway. Use of, and weaning off of, mechanical ventilation is also more challenging to carry out on patients with OI. During the procedure itself or the healing process, defective OI collagen may lead to bleeding diatheses. The safety of anesthesia is also of more concern among patients with OI, with anesthetic complications 5.6x more likely to occur when the patient has OI type III. A unique concern of anesthesia in OI is perioperative fracture—fractures sustained due to patient transfer and airway access techniques that, while routine when a patient's bones are strong, may cause injury with brittle OI bones. As an example, due to a 1972 report of a humerus fracture from a sphygmomanometer cuff sustained in an OI patient during surgery, blood pressure monitoring protocols are often modified for patients with OI, with neonatal size cuffs and machine settings being used even in adults; further, the least deformed of the patient's limbs is preferred to receive the cuff.
== Research == Research studying the safety and efficacy of corneal cross-linking is ongoing. Transepithelial or epithelium-on (epi-on) cross-linking is a technique which was first performed in 2004 in the U.S., the corneal epithelium layer is left intact. in this technique, because the epithelium is not removed, riboflavin loading requires more time than with epi-off techniques, and may be less effective, as keratoconus progression may be more likely in epi-on procedures. Contact lens-assisted cross-linking (CACXL) may be performed for people with corneal stromal thickness between 350 μm to 400 μm after epithelial removal. in this method a pre-corneal riboflavin film, a riboflavin-soaked UV barrier-free soft contact lens of negligible power and a pre-contact lens riboflavin film are used to decrease UV irradiance to safe levels at the level of the endothelium. Topography-guided crosslinking relies on an active eye tracker to allow a patterned delivery of UV light. Both the power and pattern can be programmed into the unit based on the topography of the individual's eyes. Accelerated crosslinking allows a shorter treatment time by delivering the same energy more quickly, compared to the standard crosslinking procedure, which involves 3 mW of UV-A exposure for 30 minutes. Some hospitals are using this accelerated CXL technique delivering a similar amount of UV-A energy in eight to ten minutes, following research showing the cornea may better tolerate this shorter burst of UV-A.
Sources: en.wikipedia.org
This myth spread because it was not then uncommon for black people to be refused treatment because there were not enough "Negro beds" available or because the nearest hospital only serviced white people.
== Chemical properties == Bromo(I) fluorosulfonate is a blackish-red, viscous, hydrolysis-sensitive liquid that reacts violently with water. Upon cooling, it solidifies into a glassy state. Bromo(I) fluorosulfonate reacts with iodine(I) fluorosulfonate at temperatures above 50 °C to form dibromoiodofluorosulfonate:
Using the various properties of molecules, such as the energy required to break bonds and the dipole moments of molecules, he established a scale and an associated numerical value for most of the elements — the Pauling Electronegativity Scale — which is useful in predicting the nature of bonds between atoms in molecules. In 1936, Pauling was promoted to chairman of the division of chemistry and chemical engineering at Caltech, and to the position of director of the Gates and Crellin Laboratories of Chemistry. He would hold both positions until 1958. Pauling also spent a year in 1948 at the University of Oxford as George Eastman Visiting Professor and Fellow of Balliol.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.